Evidence map›Paper›PMID 21333769›Full record

ArticleJournal of proteomics2011

Protease inhibitors as possible pitfalls in proteomic analyses of complex biological samples.

James Clifton, Feilei Huang, Marijana Rucevic, Lulu Cao, Douglas Hixson, Djuro Josic

Abstract read
In one paragraph

Article in Journal of proteomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

James CliftonDepartment of Molecular Pharmacology, Physiology and Biotechnology, Brown University, Providence, RI, USA.
Feilei Huang
Marijana Rucevic
Lulu Cao
Douglas Hixson
Djuro Josic

Funding

UCP2 expression in colon cancerP20RR017695 · NCRR · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI RAMRATNAM, BHARAT · 2002 to 2011
$15.0M
NCRR NIH HHS P20 RR017695NCRR NIH HHS P20RR017695
6 · The paper itself

Abstract

Sample preparation, especially protein and peptide fractionation prior to identification by mass spectrometry (MS), is typically applied to reduce sample complexity. The second key element in this process is proteolytic digestion, which is performed most often with trypsin. Optimization of this step is an important factor in order to achieve both speed and better performance of proteomic analysis, and tryptic digestion prior to the MS analysis has been a topic of many studies. To date, only a few studies have paid attention to the negative interaction between the proteolytic enzyme and sample components, and sample losses caused by these interactions. In this study, we demonstrated impaired activity after "in solution" tryptic digestion of plasma proteins caused by a potent trypsin inhibitor family, inter-alpha inhibitor proteins. Sample boiling followed by gel electrophoretic separation and "in-gel" digestion drastically improved both the number of identified proteins and the sequence coverage in subsequent LC-ESI-MS/MS. The present investigations show that a thorough validation is necessary when "in solution" digestion followed by LC-MS analysis of complex biological samples is performed. The parallel use of two or more different mass spectrometers can also yield additional information and contribute to further method validation.

Indexed as

Alpha-GlobulinsChromatography, High Pressure LiquidElectrophoresis, Polyacrylamide GelHL-60 CellsHumansMass SpectrometryProtease InhibitorsProteinsProteomicsTandem Mass SpectrometryTrypsinTrypsin Inhibitorsalpha-1-microglobulinAlpha-GlobulinsProtease InhibitorsProteinsTrypsinTrypsin Inhibitors

Identifiers

PMID21333769
PMCPMC3107918

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.